<  Back to Latest from EEN Success Story

Multi-targeted nano-sensor for diagnosis and drug-delivery

Enterprise Europe Network helps university spin-out to reach demonstrator-stage with a hand-held device that can tackle a range of diseases.

Written by Stefan Nardi-Hiebl on 31 July 2018

Filed under

Main Image
Blood cells under a microscope

© Shutterstock

Enterprise Europe Network has helped a university spin-out to secure investment and develop a business strategy around a sensor technology that can provide results on multiple medical conditions from a single test.

 

3PSENSE, whose innovation can be applied to both diagnosis and treatment, visited Switzerland earlier this year with a group of pharmaceutical technologies companies as part of the Innovate UK-funded Global Business Accelerator programme.

 

The Global Business Accelerator country visits organised by EEN are designed to help high-growth businesses to explore and exploit opportunities in specific countries and in market or technology areas.

 

Intellectual property strategy

 

EEN, fulfilling its role within the Innovate UK family of services, provided support before, during and after the visit, including:

 

  • a review to help define the business strategy and incorporate it into a business plan
  • help with securing investment as a loan facility
  • advice on IP strategy and negotiations with patent lawyers

 

The EEN adviser also supported the company’s application for Horizon 2020 funding through Phase 1 of the SME Instrument.

 

3PSENSE, a spin-out from University College London, is currently developing a point-of-care, hand-held diagnostic device based on its proprietary technology.

 

Simultaneous testing

 

CEO Davide Rosello said: “We think that the device may take two years to come to market, with approvals.”

 

He added: “The multi-dimensional approach of the sensor allows for simultaneous testing for infectious, non-infectious and hereditary conditions, such as haemophilia. From a single droplet of blood, it reads indicators from cells, proteins or genetic mutations.”

 

3PSENSE was created in 2016 and employs 10 staff at its London headquarters.

We have set up a two-step process with a demonstrator which can be used for diagnostic as well as for effective drug discovery.

Davide Rosello  CEO, 3PSENSE Ltd 

Associated Service